Last reviewed · How we verify

Ravicti — Competitive Intelligence Brief

Ravicti (GLYCEROL PHENYLBUTYRATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: glycerol phenylbutyrate. Area: Metabolic.

marketed glycerol phenylbutyrate Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ravicti (GLYCEROL PHENYLBUTYRATE) — Horizon Therap Us. PAA, derived from glycerol phenylbutyrate, conjugates with glutamine to form PAGN, providing an alternate pathway for nitrogen excretion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ravicti TARGET GLYCEROL PHENYLBUTYRATE Horizon Therap Us marketed glycerol phenylbutyrate 2013-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (glycerol phenylbutyrate class)

  1. Horizon Therap Us · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ravicti — Competitive Intelligence Brief. https://druglandscape.com/ci/glycerol-phenylbutyrate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: